Ironwood Pharmaceuti (NASDAQ: IRWD) announced its earnings results on Tuesday. The company reported ($0.41) earnings per share for the quarter, beating the analysts? consensus estimate of ($0.49) by $0.08. The company had revenue of $27.00 million for the quarter, compared to the consensus estimate of $16.17 million. During the same quarter in 2012, the company posted ($0.07) earnings per share. Ironwood Pharmaceuti?s revenue was down 16.1% compared to the same quarter last year.
IRWD has been the subject of a number of recent research reports. Analysts at WallachBeth initiated coverage on shares of Ironwood Pharmaceuti in a research note to investors on Tuesday, December 18th. They set a ?hold? rating on the stock. On the ratings front, analysts at Zacks upgraded shares of Ironwood Pharmaceuti from a ?neutral? rating to an ?outperform? rating in a research note to investors on Tuesday, December 18th. They now have a $12.00 price target on the stock. Finally, analysts at Cantor Fitzgerald raised their price target on shares of Ironwood Pharmaceuti from $7.00 to $8.00 in a research note to investors on Tuesday, December 18th. They now have a ?sell? rating on the stock. Six investment analysts have rated the stock with a buy rating, four have issued a hold rating, and two have given a sell rating to the company?s stock. The stock currently has a consensus rating of ?overweight? and an average price target of $15.45.
Shares of Ironwood Pharmaceuti (IRWD) opened at 14.74 on Tuesday. Ironwood Pharmaceuti (IRWD) has a 52 week low of $10.01 and a 52 week high of $15.92. The stock?s 50-day moving average is currently $11.56. The company?s market cap is $1.583 billion. Ironwood Pharmaceuticals, Inc., formerly Microbia, Inc. is an entrepreneurial pharmaceutical company that discovers, develops and focuses to commercialize medicines targeting important therapeutic needs.